Titre:
  • Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor–positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)
Auteur:McCartney, Amelia; Biagioni, Chiara; Schiavon, Gaia; Bergqvist, Mattias; Mattsson, Karin; Migliaccio, Ilenia; Benelli, Matteo; Romagnoli, Dario; Bonechi, Martina; Boccalini, Giulia; Pestrin, Marta; Galardi, Francesca; De Luca, Francesca; Biganzoli, Laura; Piccart-Gebhart, Martine; Gradishar, William W.J.; Chia, Stephen; Di Leo, Angelo; Malorni, Luca
Informations sur la publication:European journal of cancer, 114, page (55-66)
Statut de publication:Publié, 2019-06
Sujet CREF:Cancérologie
Mots-clés:Biomarker
Breast cancer
EFECT
Endocrine resistance
Prognosis
Treatment response
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0959-8049
info:doi/10.1016/j.ejca.2019.04.002
info:pii/S0959804919302230
info:scp/85065012950
info:pmid/31059974